ebola gp-specific monoclonal antibodies protect mice and guinea pigs from lethal ebola virus infection埃博拉gp-specific单克隆抗体保护小鼠和豚鼠免受致命的埃博拉病毒感染.pdfVIP

Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection 1 1 1 1,2 1,2¤a Xiangguo Qiu *, Lisa Fernando , P. Leno Melito , Jonathan Audet , Heinz Feldmann , Gary Kobinger1,2,3, Judie B. Alimonti 1,2, Steven M. Jones 1,2,3¤b 1 Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada, 2 Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada, 3 Department of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada Abstract Ebola virus (EBOV) causes acute hemorrhagic fever in humans and non-human primates with mortality rates up to 90%. So far there are no effective treatments available. This study evaluates the protective efficacy of 8 monoclonal antibodies (MAbs) against Ebola glycoprotein in mice and guinea pigs. Immunocompetent mice or guinea pigs were given MAbs i.p. in various doses individually or as pools of 3–4 MAbs to test their protection against a lethal challenge with mouse- or guinea pig-adapted EBOV. Each of the 8 MAbs (100 mg) protected mice from a lethal EBOV challenge when administered 1 day before or after challenge. Seven MAbs were effective 2 days post-infection (dpi), with 1 MAb demonstrating partial protection 3 dpi. In the guinea pigs each MAb showed partial protection at 1 dpi, however the mean time to death was significantly prolonged compared to the control group. Moreover, treatment with pools of 3–4 MAbs completely protected the majority of animals, while administration at 2–3 dpi achieved 50–100% protection. This data suggests that the MAbs generated are capable of protecting both animal species against letha